Curis Past Earnings Performance

Past criteria checks 0/6

Curis's earnings have been declining at an average annual rate of -13.8%, while the Biotechs industry saw earnings growing at 14.5% annually. Revenues have been growing at an average rate of 0.3% per year.

Key information

-13.8%

Earnings growth rate

16.2%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate0.3%
Return on equity-241.0%
Net Margin-473.0%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Curis, Inc. (NASDAQ:CRIS) Stock Catapults 63% Though Its Price And Business Still Lag The Industry

Dec 26
Curis, Inc. (NASDAQ:CRIS) Stock Catapults 63% Though Its Price And Business Still Lag The Industry

We're A Little Worried About Curis' (NASDAQ:CRIS) Cash Burn Rate

Nov 03
We're A Little Worried About Curis' (NASDAQ:CRIS) Cash Burn Rate

We're Hopeful That Curis (NASDAQ:CRIS) Will Use Its Cash Wisely

Aug 05
We're Hopeful That Curis (NASDAQ:CRIS) Will Use Its Cash Wisely

Will Curis (NASDAQ:CRIS) Spend Its Cash Wisely?

Apr 19
Will Curis (NASDAQ:CRIS) Spend Its Cash Wisely?

Is Curis (NASDAQ:CRIS) In A Good Position To Invest In Growth?

Jan 02
Is Curis (NASDAQ:CRIS) In A Good Position To Invest In Growth?

Will Curis (NASDAQ:CRIS) Spend Its Cash Wisely?

Sep 16
Will Curis (NASDAQ:CRIS) Spend Its Cash Wisely?

Curis stock soars 34% as FDA lifts partial clinical hold on emavusertib's lymphoma study

Aug 18

Curis: Asymmetric Risk And Reward

Jul 17

Here's Why We're Not Too Worried About Curis' (NASDAQ:CRIS) Cash Burn Situation

Mar 28
Here's Why We're Not Too Worried About Curis' (NASDAQ:CRIS) Cash Burn Situation

Checking In On Curis

Dec 15

Companies Like Curis (NASDAQ:CRIS) Can Afford To Invest In Growth

Dec 04
Companies Like Curis (NASDAQ:CRIS) Can Afford To Invest In Growth

We Think Curis (NASDAQ:CRIS) Can Afford To Drive Business Growth

Aug 29
We Think Curis (NASDAQ:CRIS) Can Afford To Drive Business Growth

Curis Inc.: Revisiting CA-4948 After Q2 Update

Aug 25

Curis, Inc. (NASDAQ:CRIS) Released Earnings Last Week And Analysts Lifted Their Price Target To US$16.33

Mar 19
Curis, Inc. (NASDAQ:CRIS) Released Earnings Last Week And Analysts Lifted Their Price Target To US$16.33

Announcing: Curis (NASDAQ:CRIS) Stock Soared An Exciting 625% In The Last Year

Feb 17
Announcing: Curis (NASDAQ:CRIS) Stock Soared An Exciting 625% In The Last Year

Curis Inc.: Understanding CA-4948 And IRAK-4 Inhibition

Dec 23

Curis prices equity offering at $5.75/share

Dec 09

Curis skyrockets 141% on encouraging CA-4948 data in leukemia

Dec 08

What You Need To Know About Curis, Inc.'s (NASDAQ:CRIS) Investor Composition

Dec 03
What You Need To Know About Curis, Inc.'s (NASDAQ:CRIS) Investor Composition

Curis, National Cancer Institute in development pact for anti-cancer agent

Nov 11

Revenue & Expenses Breakdown
Beta

How Curis makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:CRIS Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 2310-47190
30 Sep 2310-47180
30 Jun 2310-48180
31 Mar 2310-52190
31 Dec 2210-57200
30 Sep 2210-59200
30 Jun 2211-57200
31 Mar 2211-52190
31 Dec 2111-45170
30 Sep 2111-39160
30 Jun 2110-34140
31 Mar 2110-30130
31 Dec 2011-30120
30 Sep 2011-31120
30 Jun 2011-31120
31 Mar 2011-32120
31 Dec 1910-32120
30 Sep 199-29120
30 Jun 199-30130
31 Mar 1910-32140
31 Dec 1810-33150
30 Sep 1811-35150
30 Jun 1811-43140
31 Mar 1810-48150
31 Dec 1710-53140
30 Sep 179-57150
30 Jun 178-70160
31 Mar 178-67160
31 Dec 168-60160
30 Sep 167-63150
30 Jun 168-40130
31 Mar 168-37130
31 Dec 158-59130
30 Sep 158-51130
30 Jun 157-51130
31 Mar 1510-45120
31 Dec 1410-19120
30 Sep 149-17110
30 Jun 1415-14120
31 Mar 1415-13120
31 Dec 1315-12110
30 Sep 1315-20110
30 Jun 139-22110
31 Mar 137-24100

Quality Earnings: CRIS is currently unprofitable.

Growing Profit Margin: CRIS is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: CRIS is unprofitable, and losses have increased over the past 5 years at a rate of 13.8% per year.

Accelerating Growth: Unable to compare CRIS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CRIS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).


Return on Equity

High ROE: CRIS has a negative Return on Equity (-241.04%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.